Quick Summary
This study tested whether modafinil, a medication that promotes wakefulness, could help 14 ME/CFS patients think more clearly and feel less tired. Patients took either modafinil (at two different doses) or placebo in a blinded, controlled trial. The results were mixed: some thinking tasks improved slightly at the lower dose, but higher doses actually made some tasks harder, and fatigue ratings didn't improve at all.
Why It Matters
Modafinil has been proposed as a treatment for ME/CFS fatigue, but this controlled trial found limited and inconsistent benefits, suggesting it may not be a reliable therapeutic option for the broader patient population. Understanding which medications do not work is as important as identifying those that do, helping clinicians and patients make informed treatment decisions and directing research toward more promising interventions.
Observed Findings
What the study reports it measured.
- Modafinil 200mg reduced reaction time latency in a sustained attention task, but 400mg increased missed targets in the same task.
- Modafinil 400mg impaired performance on mental flexibility and motor speed tests compared with placebo.
- No statistically significant improvements were observed in self-reported fatigue, quality of life, or mood across either dose.
- Mixed effects on spatial planning tasks: 200mg slowed initial thinking on easy items while 400mg improved initial thinking on hard items.
Inferred Conclusions
What the authors interpret from those results.
- Chronic modafinil treatment may not provide broad clinical benefits for unselected ME/CFS patients without daytime sleepiness.
- The dose-dependent and task-specific cognitive effects suggest modafinil may not have a general cognition-enhancing effect in this population.
- A subgroup of ME/CFS patients (possibly those with concurrent sleepiness) might benefit more, warranting future targeted investigation.
Remaining Questions
- Would modafinil show greater benefit in ME/CFS patients with significant daytime sleepiness, a subgroup excluded from this trial?
- Do the mixed cognitive effects represent true drug effects or random variation given the small sample size?
- Would longer treatment periods (beyond 20 days) reveal delayed benefits on fatigue or functional outcomes?
- Are there biomarkers or patient phenotypes that could predict which ME/CFS patients might respond to modafinil?
What This Study Does Not Prove
This study does not prove modafinil is ineffective in all ME/CFS patients, particularly those with significant daytime sleepiness (a subgroup excluded from this trial). The sample size (n=14) limits statistical power, so null findings on fatigue and quality of life may reflect insufficient power rather than true absence of effect. The crossover design and short treatment windows also do not address potential benefits from longer-term use.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Randall, Delia C, Cafferty, Fay H, Shneerson, John M, Smith, Ian E, Llewelyn, Meirion B, & File, Sandra E (2005). Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome.. Journal of psychopharmacology (Oxford, England). https://doi.org/10.1177/0269881105056531
BibTeX
@article{mecfsatlas-randall-2005-chronic-treatment,
author = {Randall, Delia C and Cafferty, Fay H and Shneerson, John M and Smith, Ian E and Llewelyn, Meirion B and File, Sandra E},
title = {Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome.},
journal = {Journal of psychopharmacology (Oxford, England)},
year = {2005},
doi = {10.1177/0269881105056531},
note = {PubMed: 16272188},
url = {https://www.mecfsatlas.com/evidence/randall-2005-chronic-treatment},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/randall-2005-chronic-treatment
Contribute
Private, reviewed by a human. Not a public comment thread.